Ingevity Corporation announced that it will increase caprolactone monomer capacity at its facility in Warrington, UK, through a series of optimization projects over the next 12 months that are expected to increase Ingevity’s global monomer production capacity by more than 20% and position the company to better meet demand and more effectively serve customers. “We continue to experience growth in demand for the high-performance, sustainable solutions in our engineered polymers Capa portfolio,” s...